Self‐administered daylight‐activated photodynamic therapy for the treatment of hand eczema: A prospective proof‐of‐concept study. Issue 6 (6th October 2020)

• Record Type: Journal Article
• Authors: Kremer, Noa; Sherman, Shany; Lapidoth, Moshe; Enk, Claes D.; Leshem, Yael Anne; Mimouni, Tomer; Dudkiewicz, Dean; Hodak, Emmilia; Levi, Assi
• Is Part Of: Dermatologic therapy. Volume 33:Issue 6(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-10-06
• Subjects: chronic hand eczema -- daylight activated‐PDT -- self‐administered; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.14329
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Photodynamic therapy (PDT), traditionally used in patients with nonmelanoma skin cancer, has been found to be effective for various inflammatory skin conditions. Daylight‐activated PDT (DL‐PDT), in which the sun serves as the light source, is substantially less painful than conventional PDT. This study aimed to determine the safety and efficacy of DL‐PDT in a series of patients with chronic hand eczema (CHE). A proof‐of‐concept prospective design was used. Eight patients diagnosed with CHE at a tertiary dermatology clinic underwent DL‐PDT. The first treatment was administered at the clinic and subsequent treatments (up to four total) were self‐administered at home at 2‐week intervals. Outcome was evaluated with the Investigator Global Assessment (IGA; score 0‐4), Dermatology Life Quality Index (DLQI; score 0‐24), and blinded review of clinical photographs (graded on a quartile scale by percent improvement). There were six male and two female patients of mean age 35 years. All underwent at least three treatments. The IGA score improved by 2.5 points at 1 month, 2.7 at 3 months, and 2.2 at 6 months post‐treatment, and the DLQI score improved by 7.9, 6.6, and 6.1 points, respectively. Clinical photograph grades improved by 2.9 points at 3 months. Side effects were mild and transient. All patients had some degree of recurrence after 6 months of treatment. The self‐administered DL‐PDT is easy to perform, moderately effective, and safe to use in patients with CHE. Repeated treatments might be required to maintain remission.